trending Market Intelligence /marketintelligence/en/news-insights/trending/L1OvwV0Hae1WyFbZvLOwsg2 content esgSubNav
In This List

US FDA accepts Progenics Pharmaceuticals' tumor therapy for review

Blog

Insight Weekly: Layoffs swell; energy efficiency PE deals defy downturn; 2023 global risk themes

Blog

Insight Weekly: Energy crisis cripples Europe; i-bank incomes rise; US holiday sales outlook

Blog

Japan M&A By the Numbers: Q3 2022

Blog

Insight Weekly: Reviving nuclear power; 2023 outlook for US financials; PE funds fuel EV sector


US FDA accepts Progenics Pharmaceuticals' tumor therapy for review

The U.S. Food and Drug Administration has accepted for review the new drug application of Progenics Pharmaceuticals Inc.'s Azedra to treat malignant, recurrent or unresectable pheochromocytoma and paraganglioma.

Pheochromocytoma and paraganglioma are rare neuroendocrine tumors that arise from the cells of the autonomic nervous system.

The FDA granted Progenics' request for priority review, with an expected action date of April 30, 2018.

Azedra's application is supported by data from a phase 2b trial, conducted under a special protocol assessment with the FDA, which met the main goal that evaluated the proportion of pheochromocytoma and paraganglioma patients who achieved a 50% or greater reduction of all antihypertensive medication for at least six months.